Paul M. Dodd

1.1k total citations · 1 hit paper
10 papers, 840 citations indexed

About

Paul M. Dodd is a scholar working on Surgery, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Paul M. Dodd has authored 10 papers receiving a total of 840 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 4 papers in Epidemiology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Paul M. Dodd's work include Bladder and Urothelial Cancer Treatments (8 papers), Urinary and Genital Oncology Studies (5 papers) and Multiple and Secondary Primary Cancers (4 papers). Paul M. Dodd is often cited by papers focused on Bladder and Urothelial Cancer Treatments (8 papers), Urinary and Genital Oncology Studies (5 papers) and Multiple and Secondary Primary Cancers (4 papers). Paul M. Dodd collaborates with scholars based in United States and Spain. Paul M. Dodd's co-authors include Dean F. Bajorin, John A. McCaffrey, Harry W. Herr, Geralyn Higgins, Howard I. Scher, Mary G. Boyle, Madhu Mazumdar, Melissa Fazzari, Madhu Mazumdar and William K. Kelly and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Urologic Clinics of North America.

In The Last Decade

Paul M. Dodd

10 papers receiving 825 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy

1999 540 citations Dean F. Bajorin, Paul M. Dodd et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul M. Dodd United States	7	778	256	203	140	81	10	840
K. Jauhiainen Finland	15	547 0.7×	227 0.9×	127 0.6×	97 0.7×	158 2.0×	39	742
J. SALVADOR-BAYARRI Spain	10	916 1.2×	166 0.6×	121 0.6×	73 0.5×	308 3.8×	16	997
William Martin‐Doyle United States	8	633 0.8×	160 0.6×	127 0.6×	41 0.3×	212 2.6×	19	729
Justine Varinot France	14	388 0.5×	112 0.4×	175 0.9×	44 0.3×	121 1.5×	39	619
G Ferrante Italy	8	296 0.4×	102 0.4×	169 0.8×	182 1.3×	46 0.6×	28	513
Ulrich Gertenbach Germany	6	463 0.6×	150 0.6×	188 0.9×	18 0.1×	121 1.5×	9	578
Jesús Rodríguez-Molina Spain	7	797 1.0×	210 0.8×	123 0.6×	45 0.3×	251 3.1×	7	873
Jamie C. Riches United States	11	504 0.6×	244 1.0×	221 1.1×	24 0.2×	72 0.9×	26	679
S. Holmäng Sweden	7	446 0.6×	100 0.4×	79 0.4×	19 0.1×	121 1.5×	17	500
James Luke Godwin United States	12	408 0.5×	395 1.5×	91 0.4×	49 0.3×	34 0.4×	26	606

Countries citing papers authored by Paul M. Dodd

Since Specialization

Citations

This map shows the geographic impact of Paul M. Dodd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul M. Dodd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul M. Dodd more than expected).

Fields of papers citing papers by Paul M. Dodd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul M. Dodd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul M. Dodd. The network helps show where Paul M. Dodd may publish in the future.

Co-authorship network of co-authors of Paul M. Dodd

This figure shows the co-authorship network connecting the top 25 collaborators of Paul M. Dodd. A scholar is included among the top collaborators of Paul M. Dodd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul M. Dodd. Paul M. Dodd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Dodd, Paul M., et al.. (2000). Phase II Trial of Pyrazoloacridine as Second-Line Therapy for Patients with Unresectable or Metastatic Transitional Cell Carcinoma. Investigational New Drugs. 18(3). 247–251. 19 indexed citations

2.

Bajorin, Dean F., John A. McCaffrey, Paul M. Dodd, et al.. (2000). Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract. Cancer. 88(7). 1671–1678. 2 indexed citations

3.

Bajorin, Dean F., John A. McCaffrey, Paul M. Dodd, et al.. (2000). Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract. Cancer. 88(7). 1671–1678. 85 indexed citations

4.

Dodd, Paul M., John A. McCaffrey, Madhu Mazumdar, et al.. (2000). Evaluation of Drug Delivery and Survival Impact of Dose-Intense Relative to Conventional-Dose Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy in Urothelial Cancer. Cancer Investigation. 18(7). 626–634. 7 indexed citations

5.

Dodd, Paul M., John A. McCaffrey, Susan Hilton, et al.. (2000). Phase I Evaluation of Sequential Doxorubicin Gemcitabine Then Ifosfamide Paclitaxel Cisplatin for Patients With Unresectable or Metastatic Transitional-Cell Carcinoma of the Urothelial Tract. Journal of Clinical Oncology. 18(4). 840–840. 53 indexed citations

6.

Dodd, Paul M., John A. McCaffrey, Madhu Mazumdar, et al.. (1999). Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. Cancer. 85(5). 1145–1150. 9 indexed citations

7.

Dodd, Paul M., John A. McCaffrey, Harry W. Herr, et al.. (1999). Outcome of Postchemotherapy Surgery After Treatment With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Unresectable or Metastatic Transitional Cell Carcinoma. Journal of Clinical Oncology. 17(8). 2546–2546. 118 indexed citations

8.

Bajorin, Dean F., Paul M. Dodd, Madhu Mazumdar, et al.. (1999). Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy. Journal of Clinical Oncology. 17(10). 3173–3181. 540 indexed citations breakdown →

9.

Dodd, Paul M., Robert J. Motzer, & Dean F. Bajorin. (1998). POOR-RISK GERM CELL TUMORS. Urologic Clinics of North America. 25(3). 485–493. 6 indexed citations

10.

Dodd, Paul M. & Dean F. Bajorin. (1998). New chemotherapy regimens for metastatic bladder cancer. Current Opinion in Urology. 8(5). 413–418. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact